Sernova Corp. Stock
€0.30
Your prediction
Sernova Corp. Stock
Sernova Corp (WKN A0LBCR) is an innovative biotechnology company specializing in the development of regenerative medicine therapies. Focused on improving the treatment of chronic diseases, Sernova utilizes its proprietary Cell Pouch System™ - an implantable and scalable medical device - to house therapeutic cells for the long-term treatment of metabolic, hematologic, and neurological disorders. Listed on various stock exchanges, including Canada's TSX Venture Exchange (TSX-V), the Frankfurt Stock Exchange (FRA), and U.S. OTC (OTC:SEOVF), Sernova is driven by a mission to dramatically improve the outcomes and lives of individuals living with chronic diseases, while simultaneously offering a lucrative investment opportunity for those that believe in the potential of regenerative medicine.
Pros and Cons of Sernova Corp. in the next few years
Pros
Cons
Performance of Sernova Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Sernova Corp. | 0.680% | -6.759% | -24.501% | -48.392% | -37.325% | -70.000% | - |
| Aequus Pharmaceuticals Inc | - | 0.000% | -87.500% | -95.238% | -96.667% | -99.573% | -99.558% |
| NanoVibronix Inc. | 1.450% | -5.479% | -16.867% | -76.042% | -34.906% | - | - |
| Thermogenesis Holdings Inc. | 1.640% | 6.087% | -8.955% | -64.118% | 7.018% | -99.378% | -99.408% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.In general, Sernova's financial statements reveal a company with fluctuating levels of cash and relatively stable assets over the years. Although the company consistently reports net income losses, it seems to communicate a high level of investments in research and development. This fact could signal the company's dedication to its primary sector – Healthcare Equipment & Supplies. However, an in-depth analysis of its financial position will allow for a solid understanding of the organization's strengths and weaknesses.
*Pros: *
Increase in Total Assets: Between 2020 and 2023, Sernova's total assets increased significantly from 5,725,524 EUR to 46,960,432 CAD, demonstrating the company's ability to grow and invest in its business.
News
Sernova Welcomes Dr. Bernd Muehlenweg as Evotec’s Nominee for its Board of Directors
- Dr. Daniel Mahony to step down to pursue new commitment
LONDON, Ontario; BOSTON, Massachusetts – April 22, 2024 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a
Sernova Provides Positive Clinical and Platform Portfolio Update
- Type 1 diabetes (T1D) Cohort 2 patient data demonstrates favorable islet engraftment and long-term survival of human donor islets in the Cell Pouch
- First treated Cohort
Sernova Announces Management Developments
LONDON, Ontario; BOSTON, Massachusetts – March 11, 2024 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company focused on providing regenerative medicine